Environmental lead exposure and progressive renal insufficiency

Archives of Internal Medicine

Volumn 161, Issue 2, 2001, Pages 264-271

  Lin, Ja Liang ^a,c   Tan, Dan Tzu ^a   Hsu, Kuan Huang ^b   Yu, Chun Chen ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; EDETIC ACID; LEAD;

ADULT; AGED; ARTICLE; CHELATION THERAPY; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE COURSE; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LEAD BLOOD LEVEL; LEAD POISONING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0035931268     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.161.2.264     Document Type: Article

References (30)

1. The etiology of chronic nephritis in Queensland
2. Occupational lead nephropathy
3. Detection and treatment of occupational lead nephropathy
4. Does lead play a role in the development of chronic renal disease?
5. Impairment of renal function with increasing blood lead concentrations in the general population
6. Low-level lead exposure and renal function in the Normative Aging Study
7. A longitudinal study of low-level lead exposure and impairment of renal function: The Normative Aging Study
8. Lead nephropathy: A preventable cause of renal failure
9. Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency: A randomized, clinical trial
10. Does lead play a role in the development of renal insufficiency in some patients with essential hypertension?
11. Body lead stores and urate excretion in men with chronic renal disease
12. Disappearance of immune deposits with EDTA chelation therapy in a case of IgA nephropathy
13. Urinary N-acetyl-glucosaminidase excretion and environmental lead exposure
14. Experimental model of lead nephropathy, II: Effect of removal from lead exposure and chelation treatment with dimercaptosuccinic acid (DMSA)
15. Urinary nitrogen output as a validity test in dietary surveys
16. The role of lead in gouty nephropathy
17. The decline in blood lead levels in the United States: The National Health and Nutrition Examination Surveys (NHANES)
18. Hyperfiltration in remnant nephrons: A potential adverse response to renal ablation
19. Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease
20. Pre-end-stage renal disease care in the United States: A state of disrepair
21. Approach to volume control, cardiac preservation, and blood pressure control in the pre-end stage renal disease patients
22. Dietary protein restriction in patients with chronic renal failure
23. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study
24. Lead nephropathy, gout, and hypertension
25. Safety of EDTA lead mobilization test
26. Zinc metallopeptidase inhibitors: An oral antihypertensive treatment
27. A continuous monitoring spectrophotometric method for measurement of angiotensin-converting enzyme in human serum
28. Lead-induced hypertension: Possible role of endothelial factors
29. Preventive stategies in endothelin-induced renal failure
30. Serum creatinine and renal function